These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 33837921)

  • 1. Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study.
    Boye KS; Lage MJ; Kiljański J
    Diabetes Ther; 2021 May; 12(5):1463-1474. PubMed ID: 33837921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents.
    Boye KS; Mody R; Lage MJ; Douglas S; Patel H
    Diabetes Ther; 2020 Jul; 11(7):1513-1525. PubMed ID: 32447737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study.
    Boye KS; Thieu VT; Lage MJ; Miller H; Paczkowski R
    Adv Ther; 2022 May; 39(5):2208-2221. PubMed ID: 35316502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USA.
    Rattelman CR; Ciemins EL; Stempniewicz N; Mocarski M; Ganguly R; Cuddeback JK
    Diabetes Ther; 2021 Feb; 12(2):581-594. PubMed ID: 33460018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States.
    Ali SN; Dang-Tan T; Valentine WJ; Hansen BB
    Adv Ther; 2020 Feb; 37(2):869-882. PubMed ID: 31925649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data.
    Boye KS; Lage MJ; Thieu V; Shinde S; Dhamija S; Bae JP
    J Diabetes Complications; 2021 Sep; 35(9):107975. PubMed ID: 34176723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network.
    De Sanctis V; Soliman A; Tzoulis P; Daar S; Kattamis A; Delaporta P; Karimi M; Yassin MA; Zarei T; Saki F; Sapunarova K; Banchev A; Galati MC; Raiola G; Messina G; Campisi S; Kattamis C
    Acta Biomed; 2022 May; 93(2):e2022162. PubMed ID: 35546014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis.
    Boye KS; Lage MJ; Thieu VT
    Diabetes Ther; 2022 Feb; 13(2):367-377. PubMed ID: 35129822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation Between Different Measures of Glycemic Exposure and Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes Mellitus: An Observational Cohort Study.
    van Wijngaarden RPT; Overbeek JA; Heintjes EM; Schubert A; Diels J; Straatman H; Steyerberg EW; Herings RMC
    Diabetes Ther; 2017 Oct; 8(5):1097-1109. PubMed ID: 28921256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in Denmark.
    Lindvig A; Tran MP; Kidd R; Tikkanen CK; Gæde P
    Curr Med Res Opin; 2021 Jun; 37(6):949-956. PubMed ID: 33729871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A View Beyond HbA1c: Role of Continuous Glucose Monitoring.
    Chehregosha H; Khamseh ME; Malek M; Hosseinpanah F; Ismail-Beigi F
    Diabetes Ther; 2019 Jun; 10(3):853-863. PubMed ID: 31037553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis.
    Kostev K; Dippel FW; Rathmann W
    Diabetes Metab Syndr Obes; 2015; 8():45-8. PubMed ID: 25609990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.